SCHEMBL14901987

SCHEMBL14901987

COC(=O)c1ccc(-c2ccc(C)c(B3OC(C)(C)C(C)(C)O3)c2)c(C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.42
ROCK2 O75116 1/20 0.37
ROCK1 Q13464 1/20 0.37
EGFR P00533 1/20 0.37
ALDH1A1 P00352 4/20 0.36
PTGS2 P35354 1/20 0.36
MAPT P10636 3/20 0.36
GAA P10253 2/20 0.36
NOTUM Q6P988 1/20 0.36
LMNA P02545 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
XDH P47989 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35
PTPRC P08575 1/20 0.35
UCHL1 P09936 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1529203 0.90 SLC2A1 (0.40) SLC2A1ROCK2ROCK1EGFRALDH1A1
SCHEMBL1529198 0.90 SLC2A1 (0.40) SLC2A1ROCK2ROCK1EGFRPTGS2
SCHEMBL1506681 0.90 MAPT (0.40) SLC2A1ROCK2ROCK1EGFRALDH1A1
SCHEMBL17364631 0.89 SLC2A1 (0.39) SLC2A1ROCK2ROCK1EGFRALDH1A1
SCHEMBL960031 0.87 ALDH1A1 (0.43) ALDH1A1MAPTGAANOTUMLMNA
SCHEMBL16432813 0.82 SLC2A1 (0.43) SLC2A1ROCK2ROCK1UCHL1
SCHEMBL30963922 0.82 CA1 (0.42) ALDH1A1MAPTGAANOTUMLMNA
SCHEMBL203450 0.82 CA1 (0.42) ALDH1A1MAPTGAANOTUMLMNA
SCHEMBL14901969 0.81 LIPE (0.39) UCHL1KDM4E
SCHEMBL1528913 0.79 NOTUM (0.37) SLC2A1EGFRNOTUMCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9346825-B2 Fused bicyclic oxazolidinone CETP inhibitor MERCK SHARP & DOHME CORP. (US) 2016-05-24 US disclosed
US-20140378493-A1 Fused Bicyclic Oxazolidinone CETP Inhibitor MERCK SHARP & DOHME LLC 2014-12-25 US disclosed
US-8871738-B2 Fused bicyclic oxazolidinone CETP inhibitor MERCK SHARP & DOHME CORP. (US) 2014-10-28 US disclosed
US-20130109649-A1 FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR MERCK SHARP & DOHME LLC 2013-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378493-A1 Fused Bicyclic Oxazolidinone CETP Inhibitor CETP, MTTP, APOB SLC2A1 3099/4885ROCK2 4515/4885ROCK1 3847/4885
US-20130109649-A1 FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR CETP, MTTP, APOB SLC2A1 3099/4885ROCK2 4515/4885ROCK1 3847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.